UK University Spinouts: How They Work and Who Funds Them

UK university spinouts turn publicly funded research into companies, and for a decade the arguments about them have circled the same question: how much of the business should the university keep? That question now has something close to an agreed answer, and founders negotiating a spinout in 2026 are working from a very different baseline than founders did in 2022. Equity stakes have fallen, the terms have been standardised, and there is finally a public register of who has spun out what.

This guide covers what a spinout actually is, how the deal is structured, what stake to expect, who writes the cheques, and where the process still goes wrong.

What a spinout is, and what it is not

A spinout is a company formed to commercialise intellectual property owned by a university. The defining feature is the IP: the research was done inside the institution, the institution owns the resulting IP, and the company licenses or is assigned that IP in exchange for equity, royalties, or both.

That is different from a startup merely founded by a student or an academic. If a postgraduate builds a fintech app in their spare time using no university IP, that is a startup that happens to have a university connection. It is not a spinout, the university has no claim on it, and it should never be negotiated as though it does. The distinction matters commercially, because spinout terms exist to compensate the institution for IP it genuinely owns.

The typical spinout sits in deep tech, life sciences, materials, semiconductors or AI research: fields where the underlying invention took years of funded lab work and is protected by patents. Software spinouts are a category of their own, and are now treated differently, for reasons covered below.

Who owns what: equity, licences and royalties

Three levers get negotiated in almost every spinout deal:

Founding equity taken by the university at incorporation, in return for the IP.
The licence itself: exclusive or non-exclusive, worldwide or limited by field of use, and what happens if the company fails to commercialise.
Royalties on revenue, which sit on top of, or sometimes instead of, a larger equity stake.

Founders tend to fixate on the equity number and under-negotiate the licence. That is a mistake. A tight field-of-use restriction can cap the company’s addressable market permanently, and diligence at Series A will find it. Anti-dilution provisions matter just as much: a university stake that does not dilute alongside everyone else through subsequent rounds becomes a serious problem by the time institutional investors are at the table.

What stake do UK universities actually take in 2026?

This is where the last three years have changed things materially. The government commissioned an Independent Review of University Spin-out Companies, published in November 2023 and led by Irene Tracey, Vice-Chancellor of the University of Oxford, and Andrew Williamson, Managing Partner at Cambridge Innovation Capital. Its central finding was blunt: some UK institutions were taking founding stakes high enough to make the companies uninvestable, and the practice was costing the country companies that should have existed.

The review pointed to the University Spin-out Investment Terms (USIT) Guide, launched by TenU in April 2023, as the template the sector should converge on. The USIT Guide recommends founding equity stakes in the range of 10% to 25% for most spinouts, with flex either way depending on the maturity of the IP and how much institutional support the company received, alongside royalties of roughly 0.5% to 5%.

Software spinouts are handled separately, and more sharply. The USIT Software Guide recommends technology transfer offices take between 5% and 10% equity. The logic is that a software spinout’s value sits overwhelmingly in the team and the execution rather than in a patent portfolio that took a decade and millions of pounds of grant funding to build, so a life-sciences-shaped stake is simply mispriced.

The direction of travel is real rather than rhetorical. Average university equity stakes fell to 16.1% in 2024, down from 21.5% the previous year, a decade low. If an institution is asking for a founding stake far above the USIT range in 2026, the founder is entitled to ask, politely and directly, on what basis.

Who funds UK spinouts

Spinout funding comes from a stack of sources that mostly do not overlap with the generic pre-seed market:

University-affiliated funds. Several institutions have dedicated vehicles or long-standing partner funds that take the earliest position. They know the IP and the people, and they move before anyone external will.
Specialist deep tech and life science VCs. Firms that underwrite technical risk and long timelines rather than growth curves. They expect a clean licence and a credible route through regulatory or manufacturing risk.
Translational grant funding. Innovate UK and Research England programmes bridge the gap between a lab result and something a commercial investor will price, without taking equity.
Angels with domain expertise. Often former founders or operators in the same field. Note that a spinout’s own IP-owning university stake does not stop the company being SEIS or EIS eligible, though the structure needs checking early rather than assumed.

The practical constraint is that generalist seed VCs are frequently the wrong first call. A fund optimising for a two-year path to revenue is not a fit for a company that needs four years to get through trials or qualification, and pitching them burns time and signals inexperience.

The National Spin-Out Register

One of the more useful outcomes of the review landed in summer 2025: a National Spin-Out Register, published by the Higher Education Statistics Agency and Jisc, in partnership with Research England and the Policy Evidence Unit for University Commercialisation and Innovation at the University of Cambridge. It is a free public database of UK university spinouts.

For founders it is a benchmarking tool. Before negotiating with a technology transfer office, it is worth seeing what that institution has actually spun out, how often, and into what sectors. An office that has done forty deals behaves differently from one doing its third, and the register makes that visible rather than a matter of guesswork.

Where spinout deals still go wrong

Four failure modes recur:

Negotiating the stake in isolation. A 15% stake with a restrictive licence and no dilution is worse than a 20% stake with a clean worldwide exclusive licence that dilutes normally. Model the whole package.
Leaving the academic founder’s time undefined. If the inventor is staying in post, the company needs a written, institution-approved position on how much time they can give it and who owns what they invent next. Investors will ask, and a vague answer stalls a round.
Underestimating how long the TTO takes. Months, not weeks, particularly where multiple institutions co-own the IP. Multi-institution IP is the single most reliable way to add a quarter to a timeline.
Treating the review as binding. The Tracey review is a recommendation, not legislation. Adoption is uneven. Some institutions publish a statement of best-practice adoption; many have quietly moved; a few have not moved at all.

Frequently asked questions

Does a university always take equity in a spinout?

Not always. Some deals are structured as a licence with royalties and little or no founding equity, which can suit a company with a clear early revenue path. Equity is the norm where the IP is patent-heavy and the company will need several rounds before revenue, because royalties on nothing are worth nothing to the institution.

What is a reasonable university equity stake?

The USIT Guide recommends 10% to 25% for most spinouts and 5% to 10% for software spinouts. Average stakes across the sector fell to 16.1% in 2024. A request substantially above that range should come with a specific justification, such as unusually heavy institutional investment in the IP.

Can a spinout raise SEIS or EIS funding?

Frequently yes, but the structure has to be checked rather than assumed. The share classes, the university’s holding and the licence arrangement all interact with the qualifying conditions, and getting advance assurance from HMRC before the round is the sensible route rather than discovering a problem at completion.

Who owns IP an academic invents after the spinout is formed?

This needs settling in writing at formation. By default, IP created by an employee in the course of their employment belongs to the employer, so an academic still in post may generate IP that belongs to the university rather than the company. A well-drafted deal defines the field and the mechanism by which follow-on IP reaches the company.

How long does forming a spinout take?

Realistically several months from the first serious conversation with the technology transfer office to an incorporated company with a signed licence. Experienced offices working from standard USIT-based terms are faster. Deals involving IP co-owned by more than one institution are consistently the slowest.

Is a company founded by a student a spinout?

Only if it uses university-owned IP. A company built by a student or academic without institutional IP is an ordinary startup, and the university has no automatic claim on it. Being clear on this early avoids a negotiation that never needed to happen.

Spinouts remain one of the strongest sources of genuinely defensible UK companies, and the terms are more founder-friendly now than at any point in the last decade. The remaining variance is between institutions rather than in national policy, which means an hour spent researching how your own technology transfer office actually behaves is the best-spent hour in the whole process. More on funding routes and the UK ecosystem on the Idea London homepage.